Journal of Gastroenterology

, Volume 47, Issue 8, pp 904–911 | Cite as

Endoscopic and clinical features of gastric ulcers in Japanese patients with or without Helicobacter pylori infection who were using NSAIDs or low-dose aspirin

  • Yongmin Kim
  • Satoko Yokoyama
  • Jiro Watari
  • Kazutoshi Hori
  • Takahisa Yamasaki
  • Takuya Okugawa
  • Fumihiko Toyoshima
  • Takashi Kondo
  • Jun Sakurai
  • Junji Tanaka
  • Toshihiko Tomita
  • Tadayuki Oshima
  • Hirokazu Fukui
  • Takashi Abe
  • Takayuki Matsumoto
  • Hiroto Miwa
Original Article—Alimentary Tract



The endoscopic characteristics of gastric ulcers in patients who were using non-steroidal anti-inflammatory drugs (NSAIDs) or low-dose aspirin (LDA) and were infected with Helicobacter pylori remain unclear. We elucidated the endoscopic characteristics of gastric ulcers that occurred in the presence or absence of H. pylori infection and were associated with the use of these drugs.


A total of 379 patients with active-stage gastric ulcer were divided into three groups: H. pylori-positive patients using neither NSAIDs nor LDA (control group, n = 216), H. pylori-positive or -negative patients using NSAIDs (NSAIDs group, n = 100), and H. pylori-positive or -negative patients using LDA (LDA group, n = 63). The differences among these groups in endoscopic characteristics of the ulcers (site, multiplicity, and morphology) were determined. The influence of an antacid drug, i.e., a proton pump inhibitor (PPI) or a histamine H2 receptor antagonist (H2RA), was also investigated.


The NSAIDs group, regardless of H. pylori infection status, had higher incidences of antral, multiple, and irregularly shaped ulcers. The LDA group had a higher incidence of antral ulcers in H. pylori-negative patients and, regardless of H. pylori infection status, a higher incidence of multiple ulcers. However, the incidence of irregularly shaped ulcers in the LDA group did not differ from that in the control group. Neither the concomitant use of an antacid nor the dosing period of NSAIDs affected the results.


Our study elucidated the morphological characteristics of gastric ulcers in persons taking NSAIDs or LDA in the presence and absence of H. pylori infection. Our results may be clinically useful for inferring the causes of ulcers from their morphological characteristics.


Gastric ulcer Endoscopic characteristics Helicobacter pylori Non-steroidal anti-inflammatory drug Low-dose aspirin 



The authors have no conflicts of interest. This study was supported by a research grant from Hyogo College of Medicine.


  1. 1.
    Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994;89:S116–28.PubMedGoogle Scholar
  2. 2.
    Asaka M, Kato M, Sugiyama T, et al. Follow-up survey of a large-scale multicenter, double-blind study of triple therapy with lansoprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in Japanese peptic ulcer patients. J Gastroenterol. 2003;38:339–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Miwa H, Sakaki N, Sugano K, et al. Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients. Helicobacter. 2004;9:9–16.PubMedCrossRefGoogle Scholar
  4. 4.
    Ford AC, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev. 2006;(2):CD003840.Google Scholar
  5. 5.
    Fukuda Y, Yamamoto I, Okui M, Tonokatsu Y, Shimoyama T. Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. J Clin Gastroenterol. 1995;20(Suppl 2):S132–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359:14–22.PubMedCrossRefGoogle Scholar
  7. 7.
    Tsuji H, Kohli Y, Fukumitsu S, et al. Helicobacter pylori-negative gastric and duodenal ulcers. J Gastroenterol. 1999;34:455–60.PubMedCrossRefGoogle Scholar
  8. 8.
    Aoyama N, Shinoda Y, Matsushima Y, et al. Helicobacter pylori-negative peptic ulcer in Japan: which contributes most to peptic ulcer development, Helicobacter pylori, NSAIDS or stress? J Gastroenterol. 2000;35(Suppl 12):33–7.PubMedGoogle Scholar
  9. 9.
    Nishikawa K, Sugiyama T, Kato M, et al. Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population. Eur J Gastroenterol Hepatol. 2000;12:635–40.PubMedCrossRefGoogle Scholar
  10. 10.
    Kamada T, Hata J, Kusunoki H, et al. Eradication of Helicobacter pylori increases the incidence of hyperlipidaemia and obesity in peptic ulcer patients. Dig Liver Dis. 2005;37:39–43.PubMedCrossRefGoogle Scholar
  11. 11.
    Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22:795–801.PubMedCrossRefGoogle Scholar
  12. 12.
    García Rodríguez LA, Hernández-Díaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52:563–71.PubMedCrossRefGoogle Scholar
  13. 13.
    Niv Y, Battler A, Abuksis G, Gal E, Sapoznikov B, Vilkin A. Endoscopy in asymptomatic minidose aspirin consumers. Dig Dis Sci. 2005;50:78–80.PubMedCrossRefGoogle Scholar
  14. 14.
    Bjarnason I, Hayllar J, MacPherson AJ, Russell AS. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans. Gastroenterology. 1993;104:1832–47.PubMedGoogle Scholar
  15. 15.
    Goldstein NS, Cinenza AN. The histopathology of nonsteroidal anti-inflammatory drug-associated colitis. Am J Clin Pathol. 1998;110:622–8.PubMedGoogle Scholar
  16. 16.
    Kurahara K, Matsumoto T, Iida M, Honda K, Yao T, Fujishima M. Clinical and endoscopic features of nonsteroidal anti-inflammatory drug-induced colonic ulcerations. Am J Gastroenterol. 2001;96:473–80.PubMedCrossRefGoogle Scholar
  17. 17.
    Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005;128:1172–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3:133–41.PubMedCrossRefGoogle Scholar
  20. 20.
    Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med. 1998;105(1B):31S–8S.PubMedCrossRefGoogle Scholar
  21. 21.
    Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Al-Assi MT, Genta RM, Karttunen TJ, Graham DY. Ulcer site and complications: relation to Helicobacter pylori infection and NSAID use. Endoscopy. 1996;28:229–33.PubMedCrossRefGoogle Scholar
  24. 24.
    Nakashima S, Arai S, Mizuno Y, et al. A clinical study of Japanese patients with ulcer induced by low-dose aspirin and other non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2005;21(Suppl 2):60–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Kamada T, Hata J, Kusunoki H, et al. Endoscopic characteristics and Helicobacter pylori infection in NSAID-associated gastric ulcer. J Gastroenterol Hepatol. 2006;21(1 Pt 1):98–102.PubMedCrossRefGoogle Scholar
  26. 26.
    Waki S, Kinoshita Y, Fukui H, et al. Intragastric distribution of nonsteroidal anti-inflammatory drug-related ulcers in patients without collagen diseases. J Clin Gastroenterol. 1997;25:592–4.PubMedCrossRefGoogle Scholar
  27. 27.
    Cheatum DE, Arvanitakis C, Gumpel M, Stead H, Geis GS. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. Clin Ther. 1999;21:992–1003.PubMedCrossRefGoogle Scholar
  28. 28.
    Mizokami Y, Narushima K, Shiraishi T, Otsubo T, Narasaka T, Matsuoka T. Non-Helicobacter pylori ulcer disease in rheumatoid arthritis patients receiving long-term NSAID therapy. J Gastroenterol. 2000;35(Suppl 12):38–41.PubMedGoogle Scholar
  29. 29.
    Chiba T, Sato K, Endo M, et al. Upper gastrointestinal disorders induced by non-steroidal anti-inflammatory drugs. Hepatogastroenterology. 2005;52:1134–8.PubMedGoogle Scholar
  30. 30.
    Sakita T, Fukutomi H. Endoscopic diagnosis. In: Yoshitomi Y, editor. Ulcers of stomach and duodenum. Tokyo: Nankodo Co.; 1971. p. 197–208. (in Japanese).Google Scholar
  31. 31.
    Kimura K, Takemoto T. Endoscopic atrophy border. Endoscopy. 1969;1:1–3.CrossRefGoogle Scholar
  32. 32.
    Miki K, Ichinose M, Kawamura N, Matsushima M, Ahmad HB, Kimura M, et al. The significance of low serum pepsinogen levels to detect stomach cancer associated with extensive chronic gastritis in Japanese subjects. Jpn J Cancer Res. 1989;80:111–4.PubMedCrossRefGoogle Scholar
  33. 33.
    Kato S, Matsukura N, Tsukada K, Matsuda N, Mizoshita T, Tsukamoto T, et al. Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci. 2007;98:790–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Hart J, Hawkey CJ, Lanas A, et al. Predictors of gastroduodenal erosions in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2010;31:143–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Nishino M, Sugimoto M, Kodaira C, et al. Relationship between low-dose aspirin-induced gastric mucosal injury and intragastric pH in healthy volunteers. Dig Dis Sci. 2010;55:1627–36.PubMedCrossRefGoogle Scholar
  36. 36.
    Elta GH, Scheiman JM, Barnett JL, et al. Long-term follow-up of Helicobacter pylori treatment in non-ulcer dyspepsia patients. Am J Gastroenterol. 1995;90:1089–93.PubMedGoogle Scholar
  37. 37.
    Chan FK, Sung JJ, Chung SC, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet. 1997;350:975–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Graham DY, Lidsky MD, Cox AM, et al. Long-term nonsteroidal antiinflammatory drug use and Helicobacter pylori infection. Gastroenterology. 1991;100:1653–7.PubMedGoogle Scholar
  39. 39.
    Hawkey CJ, Karrasch JA, Szczepañski L, et al. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med. 1998;338:727–34.PubMedCrossRefGoogle Scholar
  40. 40.
    Haynes DR, Whitehouse MW, Vernon-Roberts B. The effects of some anti-arthritic drugs and cytokines on the shape and function of rodent macrophages. Int J Exp Pathol. 1991;72:9–22.PubMedGoogle Scholar
  41. 41.
    Konturek JW, Dembinski A, Konturek SJ, Stachura J, Domschke W. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology. 1998;114:245–55.PubMedCrossRefGoogle Scholar
  42. 42.
    Ding M, Kinoshita Y, Kishi K, et al. Distribution of prostaglandin E receptors in the rat gastrointestinal tract. Prostaglandins. 1997;53:199–216.PubMedCrossRefGoogle Scholar
  43. 43.
    Morimoto K, Sugimoto Y, Katsuyama M, et al. Cellular localization of mRNAs for prostaglandin E receptor subtypes in mouse gastrointestinal tract. Am J Physiol. 1997;272:G681–7.PubMedGoogle Scholar
  44. 44.
    Konturek PC. Physiological, immunochemical and molecular aspects of gastric adaptation to stress and to H. pylori-derived gastrotoxins. J Physiol Pharmacol. 1997;48:3–42.PubMedGoogle Scholar
  45. 45.
    Laine L, Takeuchi K, Tarnawski A. Gastric mucosal defense and cytoprotection: bench to bedside. Gastroenterology. 2008;135:41–60.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2012

Authors and Affiliations

  • Yongmin Kim
    • 1
    • 3
  • Satoko Yokoyama
    • 1
  • Jiro Watari
    • 1
  • Kazutoshi Hori
    • 1
  • Takahisa Yamasaki
    • 1
  • Takuya Okugawa
    • 1
  • Fumihiko Toyoshima
    • 1
  • Takashi Kondo
    • 1
  • Jun Sakurai
    • 1
  • Junji Tanaka
    • 1
  • Toshihiko Tomita
    • 1
  • Tadayuki Oshima
    • 1
  • Hirokazu Fukui
    • 1
  • Takashi Abe
    • 3
  • Takayuki Matsumoto
    • 2
  • Hiroto Miwa
    • 1
  1. 1.Division of Upper Gastroenterology, Department of Internal MedicineHyogo College of MedicineNishinomiyaJapan
  2. 2.Division of Lower Gastroenterology, Department of Internal MedicineHyogo College of MedicineNishinomiyaJapan
  3. 3.Department of GastroenterologyTakarazuka Municipal HospitalTakarazukaJapan

Personalised recommendations